Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Zhendong Li
Institution:
Liaoning Cancer Hospital & Institute
Observed institutions:
Liaocheng University,
Liaoning Cancer Hospital & Institute
ORCID:
0000-0002-3930-2888
Observed ORCID:
0000-0002-3930-2888
OpenAlex ID:
A5007073787
Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
2023
·
Yihebali Chi
, Xiangqian Zheng
, et al.
·
Clinical Cancer Research
·
49
PDF
Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
2023
·
Yansong Lin
, Shukui Qin
, et al.
·
Clinical Cancer Research
·
28
Preliminary safety and efficacy of toripalimab combined with cetuximab in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC): A phase Ib/II clinical trial.
2022
·
Ye Guo
, Zhendong Li
, et al.
·
Journal of Clinical Oncology
·
4
PDF
Efficacy and safety of the neoadjuvant chemoimmunotherapy with pembrolizumab plus docetaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck
2025
·
Jing Wang
, Wenqian Zhang
, et al.
·
Frontiers in Immunology
·
2
PDF
Thymosin α1 Combined with PD-1/PD-L1 Inhibitor Plus Chemotherapy in Platinum-Resistant Recurrent Ovarian Cancer : A Retrospective Analysis
2025
·
Hong Wang
, Lixia Wang
, et al.
·
Cancer Management and Research
·
2
PDF
Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study
2026
·
Shengyu Zhou
, Changgong Zhang
, et al.
·
Experimental Hematology and Oncology
·
1
The β-1,6-glucanase MoGlu16 is Required for Mycelia Growth and Pathogenicity of Magnaporthe oryzae
2025
·
Yanxin Wang
, Jingchen Li
, et al.
·
Current Microbiology
·
1
Phase Ib Trial of Finotonlimab Combined With SCT200 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
2026
·
Jinguan Lin
, Song Qu
, et al.
·
Cancer Medicine
PDF
FGF/FGFR Alteration Type as a Candidate Enrichment Biomarker for Gunagratinib in Recurrent or Metastatic Head and Neck Cancer: An Exploratory Analysis of Two Early-Phase Trials
2026
·
Liqiong Xue
, Guopei Zhu
, et al.
·
Targeted Oncology
Efficacy and safety of toripalimab in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): a phase 1b/2 study
2026
·
Ye Guo
, Zhendong Li
, et al.
·
Signal Transduction and Targeted Therapy
PDF
Supplementary Methods S1 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
2025
·
Yihebali Chi
, Xiangqian Zheng
, et al.
Supplementary Table S5 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
2025
·
Yihebali Chi
, Xiangqian Zheng
, et al.
Figure S1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
2025
·
Yansong Lin
, Shukui Qin
, et al.
Supplementary Tables 1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
2025
·
Yansong Lin
, Shukui Qin
, et al.
Supplementary Table S4 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
2025
·
Yihebali Chi
, Xiangqian Zheng
, et al.
Supplementary Figure S5 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
2025
·
Yihebali Chi
, Xiangqian Zheng
, et al.
Supplementary Table S3 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
2025
·
Yihebali Chi
, Xiangqian Zheng
, et al.
Supplementary Table S1 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
2025
·
Yihebali Chi
, Xiangqian Zheng
, et al.
Supplementary Figure S1 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
2025
·
Yihebali Chi
, Xiangqian Zheng
, et al.
PDF
Supplementary Table S2 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
2025
·
Yihebali Chi
, Xiangqian Zheng
, et al.
Supplementary Figure S2 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
2025
·
Yihebali Chi
, Xiangqian Zheng
, et al.
PDF
Supplementary Figure S4 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
2025
·
Yihebali Chi
, Xiangqian Zheng
, et al.
PDF
Data from Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer
2024
·
Yansong Lin
, Shukui Qin
, et al.
Figure S1 from Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer
2024
·
Yansong Lin
, Shukui Qin
, et al.
Supplementary Tables 1 from Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer
2024
·
Yansong Lin
, Shukui Qin
, et al.
Show more works
View as search
Works count:
49
Citation count:
87
H-index:
3
I10-index:
2
Year
Topic
Type